Coya Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

COYA$2.99+6.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED BALANCE SHEETS

(unaudited)
	June 30,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$29,757,328	$38,339,762
Prepaids and other current assets	3,670,319	5,968,666
Total current assets	33,427,647	44,308,428
Fixed assets, net	24,908	38,588
Total assets	$33,452,555	$44,347,016
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$931,344	$1,588,128
Accrued expenses	2,838,685	1,388,060
Deferred collaboration revenue	731,075	848,286
Total current liabilities	4,501,104	3,824,474
Deferred collaboration revenue	641,158	945,447
Total liabilities	5,142,262	4,769,921
Commitments and contingencies (Note 6)
Stockholders' equity:
Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of June 30, 2025 or December 31, 2024	-	-
Common stock, $0.0001 par value; 200,000,000 shares authorized; 16,724,998 and 16,707,441 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	1,673	1,671
Additional paid-in capital	82,447,524	80,312,594
Accumulated deficit	(54,138,904)	(40,737,170)
Total stockholders' equity	28,310,293	39,577,095
Total liabilities and stockholders' equity	$33,452,555	$44,347,016

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.